Friday, November 4, 2022 Daily Archives

ReiThera opens Italy viral vector production plant

by

ReiThera has expanded its large-scale viral vector manufacturing capabilities at its Castel Romano Technopole plant through receiving operational authorization from the Italian Medicines Agency. According to the contract development manufacturing organization (CDMO), the recently opened 1,500 square meter facility located close to Rome will have production scales of up to 3,000 L and produce viral vectors for vaccines and gene therapies. “Thanks to the operational authorization of this expanded facility, the ReiThera team, which combines high-level scientific knowledge with extensive…

November 4, 2022

CSL Seqirus to access Arcturus’ sa-mRNA vax tech

by

Through the collaboration and license agreement, CSL Seqirus will access Arcturus Therapeutics’ late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology.  Arcturus will grant CSL Seqirus (part of CSL Limited) a license to its sa-mRNA technology in order to support the research, development, production, and commercialization of vaccines for SARS-CoV-2, as well as influenza, pandemic preparedness, and a further three global respiratory infectious diseases. “This collaboration on next generation mRNA is another example of CSL’s relentless pursuit of disruptive innovation when public…

November 4, 2022

Catalent cuts full year forecast citing COVID, currencies and costs

by

Catalent has cut its 2023 forecast after lower COVID-19 related product demand, inflation and currency headwinds impacted Q1 biologics revenue. The contract development manufacturing organization (CDMO) reported revenue for the three months ended September 30 of $1.02 billion, roughly the same as it was in the comparable period in 2021. Meanwhile, net income fell 52% to $61 million. The contribution from Catalent’s biologics business – which includes large molecule drug development and manufacturing as well as cell and gene therapies…

November 4, 2022